Download PDF
Aktuelle Rheumatologie 2005; 30(1): 59-65
DOI: 10.1055/s-2005-857939
Originalarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Differenzierte Therapie der Keratokonjunctivitis sicca beim Sjögren-Syndrom

Management of Keratoconjunctivitis Sicca in Sjögren’s SyndromeE. M. Messmer1
  • 1Augenklinik der Ludwig-Maximilians-Universität, München
Further Information

Publication History

Publication Date:
21 February 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Keratokonjunctivitis sicca bei Sjögren-Syndrom ist eine Erkrankung, die zu stark beeinträchtigenden Symptomen sowie zu Hornhautkomplikationen verbunden mit Visusverlust führen kann. Neben entzündlichen Faktoren werden hormonelle Veränderungen sowie neuronale Störungen in der Pathogenese diskutiert. Die Therapie besteht unter anderem aus symptomatischen Maßnahmen (Schutzbrillen, Luftbefeuchter), Beseitigung von Lidanomalien und Refraktionsfehlern, Behandlung einer assoziierten Blepharitis sowie im Absetzen bestimmter Medikamente. Neben einer Vielzahl von Tränenersatzprodukten und autologem Serum stehen heute im Ansatz kausale Medikamente zur Verfügung, wie lokale Kortikosteroide, topisches Ciclosporin A und orale (M1)/M3-Agonisten. Lokale Androgene und Sekretagoga wie Diquafosol-Tetrasodium und 15(S)-HETE zur Therapie des Trockenen Auges sind in klinischer Erprobung.

Abstract

Keratoconjunctivitis sicca in patients with Sjögren’s syndrome is typically associated with severe subjective symptoms and may lead to corneal complications and visual loss. Inflammation, hormonal factors and neuronal dysregulations are discussed as pathogenetic factors. Therapy includes safety goggles, humidifiers, correction of lid anomalies and refraction deficits, treatment of associated blepharitis and discontinuance of specific medications. Besides numerous artificial tears solutions and autologous serum, treatments became available with topical steroids, cyclosporin A and oral muscarinic agonists that target the basic disease mechanisms. Topical androgens and secretagogues such as diquafosol tetrasodium and 15(S)-HETE are in clinical evaluation for the treatment of keratoconjunctivitis sicca.

Schlüsselwörter

Keratokonjunctivitis sicca - Sjögren-Syndrom - kausale Medikamente

Key words

Keratoconjunctivitis sicca - Sjögren’s syndrome - treatments targeting basic disease mechanisms

Literatur

  • 1 Balaram M, Schaumberg D A, Dana M R. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome.  Am J Ophthalmol. 2001;  131 30-36
    CrossrefPubMedGoogle Scholar
  • 2 Brückner R. Über einen erfolgreich mit Perandren behandelten Fall von Sjögren’schem Symptomenkomplex.  Ophthalmologica. 1945;  110 37-42
    PubMedGoogle Scholar
  • 3 Christensen M T, Cohen S, Rinehart J. et al . Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye.  Curr Eye Res. 2004;  28 55-62
    CrossrefPubMedGoogle Scholar
  • 4 Cohen E J. Punctal occlusion.  Arch Ophthalmol. 1999;  117 389-390
    PubMedGoogle Scholar
  • 5 Cummins M J, Papas A, Kammer G M. et al . Treatment of primary Sjögren’s syndrome with low-dose human interferon alpha administered by the oromucosal route: combined phase III results.  Arthritis Rheum. 2003;  49 585-593
    CrossrefPubMedGoogle Scholar
  • 6 Dinslage S, Stoffel W, Diestelhorst M. et al . Tolerability and safety of two new preservative-free tear film substitutes.  Cornea. 2002;  21 352-355
    CrossrefPubMedGoogle Scholar
  • 7 Fox R I, Chan R, Michelson J B. et al . Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca.  Arthritis Rheum. 1984;  27 459-461
    PubMedGoogle Scholar
  • 8 Fox R I, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of sjögren’s syndrome.  Clin Immunol. 2001;  101 249-263
    CrossrefPubMedGoogle Scholar
  • 9 Fujihara T, Murakami T, Fujita H. et al . Improvement of corneal barrier function by the P2Y2 agonist INS365 in a rat dry eye model.  Invest Ophthalmol Vis Sci. 2001;  42  96-100
    PubMedGoogle Scholar
  • 10 Gamache D A, Wei Z Y, Weimer L K. et al . Preservation of corneal integrity by the mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced dry eye.  Adv Exp Med Biol. 2002;  506 335-340
    PubMedGoogle Scholar
  • 11 Gamache D a, McDonough T J, Roberts L. et al . The mucin secretagogue 15(S)-HETE protects the cornea and improves tear film integrity in a rabbit model of lacrimal gland inflammation induced dry eye.  Ophthalmol Vis Sci. 2003;  44 2498
    PubMedGoogle Scholar
  • 12 Gao J, Schwalb T A, Addeo J V. et al . The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical cyclosporin A therapy.  Cornea. 1998;  17 654-663
    PubMedGoogle Scholar
  • 13 Geerling G, Hartwig D. Autologe Serum-Augentropfen zur Therapie der Augenoberfläche.  Ophthalmologe. 2002;  99 949-959
    CrossrefPubMedGoogle Scholar
  • 14 Geerling G, Honnicke K, Schröder C. et al . Quality of salivary tears following autologous submandibular gland transplantation for severe dry eye.  Graefe’s Arch Clin Exp Ophthalmol. 1999;  237 546-553
    PubMedGoogle Scholar
  • 15 Goto E, Yagi Y, Kaido M. et al . Improved functional visual acuity after punctal occlusion in dry eye patients.  Am J Ophthalmol. 2003;  135 704-705
    CrossrefPubMedGoogle Scholar
  • 16 Goto E, Yukiko Y, Matsumoto Y. et al . Impaired functional visual acuity of dry eye patients.  Am J Ophthalmol. 2002;  133 181-186
    CrossrefPubMedGoogle Scholar
  • 17 Gündüz K, Özdemir Ö. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome.  Acta Ophthalmol. 1994;  72 438-442
    PubMedGoogle Scholar
  • 18 Heiligenhaus A, Koch J M, Kruse F E. et al . Diagnostik und Differenzierung von Benetzungsstörungen.  Ophthalmologe. 1995;  92 6-11
    PubMedGoogle Scholar
  • 19 Hemady R, Chu W, Foster C S. Keratoconjunctivitis sicca and corneal ulcers.  Cornea. 1990;  9 170-173
    PubMedGoogle Scholar
  • 20 Iwabuchi Y, Katagiri M, Masuhara T. Salivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL7lpr mice.  Arch Int Pharmacodyn Ther. 1994;  328 315-325
    PubMedGoogle Scholar
  • 21 Jones D T, Monroy D, Ji Z. et al . Sjögren’s syndrome : cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium.  Invest Ophthalmol Vis Sci. 1994;  35 3493-3504
    PubMedGoogle Scholar
  • 22 Kaswan R L, Salisbury M A, Ward D A. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops.  Arch Ophthalmol. 1989;  107 1210-1216
    CrossrefPubMedGoogle Scholar
  • 23 Khurshudian A V. A pilot study to test the efficacy of oral administration of interferon-α lozenges to patients with Sjögren’s syndrome.  Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;  95 38-44
    CrossrefPubMedGoogle Scholar
  • 24 Krachmer J H, Laibson P R. Corneal thinning and perforation in Sjögren’s syndrome.  Am J Ophthamol. 1974;  78 917-920
    PubMedGoogle Scholar
  • 25 Laibovitz R A, Solch S, Andriano K. Pilot trial of cyclosporine 1 % ophthalmic ointment in the treatment of keratoconjunctivitis sicca.  Cornea. 1993;  12 315-323
    CrossrefPubMedGoogle Scholar
  • 26 Leloup C, Michaelson D M, Fisher A. et al . M1 muscarinic receptors block caspase activation by phosphoinositide 3-kinase- and MAPK/ERK-independent pathways.  Cell Death Differ. 2000;  7 825-833
    CrossrefPubMedGoogle Scholar
  • 27 Lemp M A. Report of the National Eye Institute/Industry Workshop on clinical trials in dry eye.  CLAO J. 1995;  21 221-232
    PubMedGoogle Scholar
  • 28 Liu Z, Pflugfelder S C. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency.  Ophthalmology. 1999;  106 939-943
    CrossrefPubMedGoogle Scholar
  • 29 Marsh P, Pflugfelder S C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in sjögren syndrome.  Ophthalmology. 1999;  106 811-816
    CrossrefPubMedGoogle Scholar
  • 30 Misawa M, Ohmori S, Yanaura S. Effects of bromhexine on the secretions of saliva and tears.  Jpn J Pharmacol. 1985;  39 241-250
    PubMedGoogle Scholar
  • 31 Moore C P, McHugh J B, Thorne J G. et al . Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model.  Invest Ophthalmol Vis Sci. 2001;  42 653-659
    PubMedGoogle Scholar
  • 32 Mundasad M V, Novack G D, Allgood V E. et al . Ocular safety of INS365 ophthalmic solution: a P2Y2 agonist in healthy subjects.  J Ocul Pharmacol Ther. 2001;  17 173-179
    CrossrefPubMedGoogle Scholar
  • 33 Murakami T, Fujihara T, Nakamura M. et al . P2Y2 receptor stimulation increases tear fluid secretion in rabbits.  Curr Eye Res. 2000;  21 782-787
    CrossrefPubMedGoogle Scholar
  • 34 Murakami T, Fujihara T, Nakamura M. et al . P2Y2 receptor elicits PAS-positive glycoprotein secretion from rabbit conjunctival goblet cells in vivo.  J Ocul Pharmacol Ther. 2003;  19 345-352
    CrossrefPubMedGoogle Scholar
  • 35 Nepp J, Wedrich A, Akramian A. et al .Dry eye treatment with acupuncture. Sullivan DA Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2 New York (USA); Plenum Press 1998: 1011-1016
    Google Scholar
  • 36 Ono M, Takamura E, Shinozaki K. et al . Therapeutic effect of cevimeline on dry eye in patients with sjögren’s syndrome: a randomized, double-blind clinical study.  Am J Ophthalmol. 2004;  138 6-17
    CrossrefPubMedGoogle Scholar
  • 37 Petrone D, Condemi J J, Fife R. et al . A double-blind, randomized, placebo-controlled study of cevimeline in sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca.  Arthritis Rheum. 2002;  46 748-754
    CrossrefPubMedGoogle Scholar
  • 38 Pflugfelder S C, Solomon A, Stern M E. The diagnosis and management of dry eye.  Cornea. 2000;  19 644-649
    CrossrefPubMedGoogle Scholar
  • 39 Pleyer U, Dörner T. Sjögren Syndrom. Messmer EM Diagnose und Therapie der Keratoconjunctivitis sicca Bremen; UNI-Med-Verlag 2001: 80-88
    Google Scholar
  • 40 Sall K, Stevenson O D, Mundorf T K. et al . Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease.  Ophthalmology. 2000;  107 631-639
    CrossrefPubMedGoogle Scholar
  • 41 Schaumberg D A, Buring J E, Sullivan D A. et al . Hormone replacement therapy and dry eye syndrome.  JAMA. 2001;  286 2114-2119
    CrossrefPubMedGoogle Scholar
  • 42 Schiffman R M, Walt J G, Jacobsen G. et al . Utility assessment among patients with dry eye disease.  Ophthalmology. 2003;  110 1412-1419
    CrossrefPubMedGoogle Scholar
  • 43 Schröder C, Sieg P, Framme C. et al . Autotransplantation der Unterkieferspeicheldrüse bei absoluter Keratoconjunctivitis sicca.  Klin Monatsbl Augenheilkd. 2002;  219 494-501
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Shiozawa K, Tanaka Y, Yoshihara R. et al . Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia inpatients with Sjögren’s syndrome.  J Interferon Cytokine Res. 1998;  18 255-262
    PubMedGoogle Scholar
  • 45 Smith J K, Siddiqui A A, Modica L A. et al . Interferon upregulated gene expression of Aquaporin-5 in human parotid glands.  J Interferon Cytokine Res. 1999;  19 929-935
    CrossrefPubMedGoogle Scholar
  • 46 Solomon A, Dursun D, Liu Z. et al . Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease.  Invest Ophthalmol Vis Sci. 2001;  42 2283-2292
    PubMedGoogle Scholar
  • 47 Stern M E, Beuerman R W, Fox R I. et al . The pathology of dry eye: the interaction between the ocular surface and lacrimal glands.  Cornea. 1998;  17 584-589
    CrossrefPubMedGoogle Scholar
  • 48 Stern M E, Gao J, Schwalb T A. et al . Conjunctival T-cell subpopulations in Sjögren’s and non-Sjögren’s patients with dry eye.  Invest Ophthalmol Vis Sci. 2002;  43 2609-2614
    PubMedGoogle Scholar
  • 49 Stevenson D, Tauber J, Reis B L. The cyclosporin A phase 2 study group. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease.  Ophthalmology. 2000;  107 967-974
    CrossrefPubMedGoogle Scholar
  • 50 Sullivan D A, Belanger A, Cermak J M. et al . Are women with Sjögren’ssyndrome androgen-deficient?.  J Rheumatol. 2003;  30 2413-2419
    PubMedGoogle Scholar
  • 51 Sullivan D A, Edwards J A. Androgen stimulation of lacrimal gland function in mouse models of sjögren’s syndrome.  J Steroid Biochem Molec Biol. 1997;  60 237-245
    PubMedGoogle Scholar
  • 52 Sullivan D A, Krenzer K L, Sullivan B D. et al . Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency?.  Invest Ophthalmol Vis Sci. 1999;  40 1261-1265
    PubMedGoogle Scholar
  • 53 Sullivan D A, Sullivan B D, Evans J E. et al . Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye.  Ann N Y Acad Sci. 2002;  966 211-222
    PubMedGoogle Scholar
  • 54 Sullivan R M, Cermak J M, Papas A S. et al . Economic and quality of life impact of dry eye symptoms in women with Sjögren’s syndrome.  Adv Exp Med Biol. 2002;  506 1183-1188
    PubMedGoogle Scholar
  • 55 Tai M C, Cosar C B, Cohen E J. et al . The clinical efficacy of silicone punctal plug therapy.  Cornea. 2002;  21 135-139
    CrossrefPubMedGoogle Scholar
  • 56 Tauber J, Davitt W F, Bokosky J E. et al . Double masked, placebo-contolled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.  Invest Ophthalmol Vis Sci. 2003;  44 3738
    PubMedGoogle Scholar
  • 57 Tsubota K, Goto E, Fujita H. et al . Treatment of dry eye by autologous serum application in sjögren’s syndrome.  Br J Ophthalmol. 1999;  83 390-395
    PubMedGoogle Scholar
  • 58 Vendramini A C, Soo C, Sullivan D A. Testosterone-induced suppression of autoimmune disease in lacrimal tissue of a mouse model (NZB/NZWF1) of sjögren’s syndrome.  Invest Ophthalmol Vis Sci. 1991;  32 3002-3006
    PubMedGoogle Scholar
  • 59 Vivino F B, Al-Hashimi I, Khan Z. et al . Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with sjögren’s syndrome.  Arch Intern Med. 1999;  159 174-181
    CrossrefPubMedGoogle Scholar
  • 60 Worda C, Nepp J, Huber J C. et al . Treatment of keratoconjunctivitis sicca with topical androgen.  Maturitas. 2001;  37 209-212
    CrossrefPubMedGoogle Scholar
  • 61 Yerxa B R, Mundasad M, Sylvester R N. et al . Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.  Adv Exp Med Biol. 2002;  506 1251-1257
    PubMedGoogle Scholar
  • 62 Yoshida A, Fujihara T, Nakata K. Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice.  Exp Eye Res. 1999;  68 541-546
    CrossrefPubMedGoogle Scholar

Dr. Elisabeth M. Messmer

Augenklinik der Ludwig-Maximilians-Universität

Mathildenstraße 8

80336 München

Phone: 0 89/51 50-38 00

Fax: 0 89/51 60-51 60

Email: emessmer@med.uni-muenchen.de

      >